title: LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.
abstract: Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its pathogenesis is poorly understood. We evaluated 69 cases of PCNSL for the expression of HGAL (also known as GCSAM), LMO2 and BCL6 - genes associated with DLBCL prognosis and pathobiology, and analysed their correlation to survival in 49 PCNSL patients receiving MTX-based therapy. We demonstrate that PCNSL expresses LMO2, HGAL(also known as GCSAM) and BCL6 proteins in 52%, 65% and 56% of tumours, respectively. BCL6 protein expression was associated with longer progression-free survival (P = 0·006) and overall survival (OS, P = 0·05), while expression of LMO2 protein was associated with longer OS (P = 0·027). Further research is needed to elucidate the function of BCL6 and LMO2 in PCNSL.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
authors.forename: Chen
authors.initials: C
authors.lastname: Lossos
authors.forename: Soley
authors.initials: S
authors.lastname: Bayraktar
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Weinzierl
authors.forename: Sheren F
authors.initials: SF
authors.lastname: Younes
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Hosein
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Tibshirani
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Sutton Posthumus
authors.forename: Lisa M
authors.initials: LM
authors.lastname: DeAngelis
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Raizer
authors.forename: David
authors.initials: D
authors.lastname: Schiff
authors.forename: Lauren
authors.initials: L
authors.lastname: Abrey
authors.forename: Yasodha
authors.initials: Y
authors.lastname: Natkunam
authors.forename: Izidore S
authors.initials: IS
authors.lastname: Lossos
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D016543:Central Nervous System Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D004268:DNA-Binding Proteins / Q000378:metabolism*; D006801:Humans; D053208:Kaplan-Meier Estimate; D060588:LIM Domain Proteins / Q000378:metabolism*; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D051560:Proto-Oncogene Proteins c-bcl-6; D016896:Treatment Outcome
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C084103:BCL6 protein, human; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D060588:LIM Domain Proteins; C085117:LMO2 protein, human; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D051560:Proto-Oncogene Proteins c-bcl-6; D008727:Methotrexate
keywords: BCL6; HGAL; LMO2; PCNSL; prognosis